Hind.Bio Science (532041)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹8.11, Hind.Bio Science is a ₹8-crore microcap that offers almost nothing a Graham investor can value. The latest quarter reports zero sales and zero net profit, while reported sales growth is flat. A 300% profit growth number and a PEG of 0.19 look eye-catching, but with no current revenue, that profit is a tiny, unreliable base — likely a base effect or non-operating item, not durable compounding. The P/E of 55.71 and P/B of 10.96 against a book value of just ₹0.74 mean the market is already paying a heavy price for hope. ROE of 17.35% may sound nice, but ROCE of only 2.95% exposes the underlying business: on capital employed, returns are almost negligible. The Piotroski F-score of 6/9 is acceptable, but it cannot compensate for zero sales and undisclosed promoter holding. The FairStock score is N/A because of insufficient data, and that itself is a warning. There is no dividend, so every rupee of return must come from price appreciation — not a margin of safety. In the 52-week range of ₹5.00-₹9.92, the stock is trading in the upper half, so I am not being offered a distressed price. This is not a wonderful business with a moat; it is a speculative shell with a software-products label and a bio-science name. As Graham said, price is what you pay, value is what you get. I see no clear value here, only a small market cap and hope. Without meaningful revenue, higher return on capital, and proper disclosure, I cannot call it an investment. I would rather wait for a margin of safety, or pass altogether. For an Indian retail investor, this belongs in the 'too hard' pile unless the company starts proving itself with actual numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer